global-hematology-2019-scientifictracks

Hematology and Blood Disorders | Volume 2

Page 22

July 25-26, 2019 | Amsterdam, Netherlands

OF EXCELLENCE

IN INTERNATIONAL

MEETINGS

YEARS

Global Hematology 2019

International Conference on

HEMATOLOGY AND

BONE MARROW TRANSPLANTATION

OPTIMIZING FUTURE EXCELLENCE IN HEMATOLOGY DIAGNOSIS AND TRANSPLANTATION

Ayesha J

Shifa International Hospital, Islamabad

Shifa Tameer-e-Millat University, Islamabad

ematological malignancies are complex, not only towards diagnostic end but towards defining prognos-

tic groups and available treatment options. In the recent past with a huge influx of newer options, the

things are improving at the management end of the hematological cancers. The diseases which were labeled

as“Death warrants”have now become“Chronic ailments”. Though there still exists a wide gap between a“Good

productive life” and “Increased survival ship” after the diagnosis of a hematological cancer, the distances are

definitely bridged. With an individualized approach now, after defining genetic lesions, newer immune, tar-

geted and vaccine therapies are now in the market to hit the cancer from different angles. At the same time

affordability, after the technical provision of a treatment modality remains the highest concern for the fatally

affected patients. Peripheral blood stem cell (PBSC) transplants remain one curative option for the develop-

ing world like Pakistan, where CART-T and Immune therapies are simply not financially realistic. Authors have

performed 183 autologous and allogenic PBSC transplants in our tertiary care hospital for various hematolog-

ical malignancies including acute leukaemias, multiple myeloma and lymphoma. While autologous showing

better overall three and five year survival as compared to allogenic transplants, this modality is a ray of hope

for the longer survival in AML like otherwise fatal disorders. They started transplant services in year 2013, with

the ideal inclusion criteria of “Disease in first remission” after the diagnosis of a blood malignancy, but over a

course of five years had to include many young patients with multiple relapses and without initial prognostic

genetic profiling. Two methods for cryopreservation of the harvests at -800C were used; One with DMSO and

saline only and the other with addition of 6% albumin. A review of survival ship and engraftment shows better

results with the first method.

Ayesha J, Hematol Blood Disord 2019, Volume 2

Ayesha J qualified as a Medical Doctor at the age of 23 years from king Edward Medical University, Lahore. She passed her member-

ship and fellowship examinations in year 2002 and 2003 from CPSP Pakistan after completing four years of rigorous training. She

got training in cytogenetics and FISH techniques from UCLA, USA in year 2008 for the diagnosis and prognosis in hematological

malignancies. She became Professor of Pathology in year 2011 after 12 years of under graduate teaching. She cleared her qualifying

examination from council of Canada in year 2012. Currently she is working in a JCIA accredited tertiary care hospital as Consultant

Hematologist since 2008. With over 25 publications in national and indexed journals, she is a supervisor and program director in

the subject of Hematology of CPSP Pakistan, since 2013 and has the credit of training five young hematologists, while six doctors

are still under her training.

BIOGRAPHY